Current Status of the Liver Transplant Program

Marco A. Olivera MD, FACP, FAASLD

Michael F. Sorrell Distinguished Chair in Internal Medicine

Associate Program Director

Transplant Hepatology Fellowship



Disclosures


I have no financial disclosures or conflict of interests to declare.

My presentation will NOT include any FDA non-approved medications

My presentation will include data that has not been published yet











UNOS










2024 in brief:


- More than 48,000 organ transplants
- More than 7,000 living donors
- Nearly 17,000 deceased organ donors
- More than 55 percent increase in organ transplants since 2015
- More than 10% increase in lung transplants over 2023
- More than 7% increase in liver transplants over 2023
- Nearly 8,200 donors age 50+

Read the press release)






Status of the Liver Transplant Program 2021-2025.































Outreach NE-IA





Outreach NE-SD





Academic/Research Achievements


- 3 Top Teacher awards (UNMC)
- 1 Most Valuable Program Director Award (UNMC)
- > 1 UNMC E-learning Award for two of our Mentees
- > 1 AASLD Liver Scholar (one of our Mentees)
- 1 ACG Outstanding Poster Presentation Award
- 2 Book Chapters
- 4 Published Manuscripts
- Multiple National and International Presentations
- > 1 Patent filed




Actions









ALD Analysis 2021 UNMC


Characteristic		Mean +/- SD (or n,%)
Sobriety Prior to Listing		33.02 +/- 13.3 Median 13.3
Laboratory Tests		
	BAC	<10 (Negative) in 187/189 (98.9%) Missing n=2
	PETH	Negative in 15/189 (7.9%) Missing n=174



			Cor				
Neur	SW Recommendations		Compliance	Compliance while listed	List	Total	al
Com	Compliance	Observed % within row	79.0 %	8 12.9%	5 8.1 %	62 100.0%	15
Suita	Compliance while listed	Observed % within row	0 0.0%	100.0%	0 0.0%	4 100.0%	70 1%
NA	Suitable	Observed % within row	3 2.5%	12 9.9%	106 87.6%	121 100.0%	3
Not S	NA	Observed % within row	0 0.0%	1 100.0%	0 0.0%	1 100.0%	1
Total	Not Suitable	Observed % within row	1 100.0%	0.0%	0 0.0%	1 100.0%	89
	Total	Observed % within row	53 28.0%	25 13.2%	111 58.7%	189 100.0%	




Etiology of liver diseases requiring OLT





Impact of AUD in post OLT survival





Challenges

- QIP 2021: 14.3% returned to ANY alcohol use post OLT.
- > QIP 2021: 7.9% had SUSTAINED alcohol use post OLT.
- > 11.5% AAH returned to any drinking (Mathurin et al)(1)
- 10% AAH returned to drinking 1 year post OLT (Lee) (2)
- > 17% AAH returned to drinking 3 years port OLT (Lee)(2)
- Non-published data suggest 30-80% recurrence of AUD post OLT for AAH
- QIP 2024-2025: ? will tell you next year



Moving Forward

- QIP Moliya P, Ginnaram S, Olivera M, Khoury N, Pradhan F
- Analyze ALL patients transplanted for AUD/ALD 2022-2024 including those with AAH
- Innovations in management (Addiction Psychiatry management; Terlipressin?)
- Graft and Patient survival, sobriety, recurrence of AUD
- Compare results with QIP 2021
- Need to redefine "Success" in AUD/ALD?



